Form 4 for CTKB Cytek Biosciences, Inc.
Accepted 2023-02-23 00:00:00 ET · period of report 2022-09-08 · accession 0001209191-23-012351 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-23 | 2022-09-08 | CTKB | Jeanmonod Patrik | CFO | M - OptEx | $0.4 | +40.0K | 116.1K | +53% | +$16.0K |
| D | 2023-02-23 | 2022-09-08 | CTKB | Jeanmonod Patrik | CFO | M - OptEx | $0.00 | -40.0K | 202.7K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-08 | M | A | 40,000 | $0.4 | 116,132 | D | — | — | (F1) The Forms 4 filed after the date of the option exercise reported in this Form 4 incorrectly underreported total ownership by 40,000 shares. The number of securities beneficially owned following this option exercise is reflected as of February 17, 2022. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2022-09-08 | M | D | 40,000 | $0.00 | 202,661 | D | $0.4 · — to 2029-01-11 | 40,000 Common Stock | (F2) The shares subject to the option vest as follows: 25% of the shares subject to the option vests on October 15, 2019; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years. |